ORIGINAL ARTICLE
Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters
Submission date: 2016-01-26
Final revision date: 2016-03-22
Acceptance date: 2016-03-24
Publication date: 2016-08-02
Pol J Pathol 2016;67(2):108-113
KEYWORDS
TOPICS
ABSTRACT
We aimed to determine the presence of SKI-interacting protein (SKIP) expression in malignant pleural mesothelioma (MPM) and its effect on prognosis by investigating SKIP correlation with the Ki-67 proliferation index and prognostic parameters.
Pathological preparations of the patients diagnosed with MPM between 2006 and 2012 were evaluated. Immunohistochemical analyses were performed to evaluate the expression of SKIP and the Ki-67 proliferation index. Correlations between SKIP expression, clinicopathological factors and survival were investigated. Survival data were calculated using the Kaplan–Meier method, and Cox regression analysis was used to evaluate the prognostic value of the variables.
In total, 52 patients were evaluated in the study; 36 of them were male and 16 were female. The mean age of the patients was 62.3 ±12.2 years.
The median overall survival period was 8.5 months. Factors negatively affecting general survival in the univariate analysis included high SKIP expression, Ki-67 proliferative index over 30%, presence of non-epithelioid type MPM and stage III-IV disease (p < 0.05).
Cox regression analysis revealed that high SKIP expression, high Ki-67 proliferative index and presence of non-epithelioid type MPM are independent factors that affect the survival rate.
Higher SKIP expression is associated with poor prognosis in MPM.
Pathological preparations of the patients diagnosed with MPM between 2006 and 2012 were evaluated. Immunohistochemical analyses were performed to evaluate the expression of SKIP and the Ki-67 proliferation index. Correlations between SKIP expression, clinicopathological factors and survival were investigated. Survival data were calculated using the Kaplan–Meier method, and Cox regression analysis was used to evaluate the prognostic value of the variables.
In total, 52 patients were evaluated in the study; 36 of them were male and 16 were female. The mean age of the patients was 62.3 ±12.2 years.
The median overall survival period was 8.5 months. Factors negatively affecting general survival in the univariate analysis included high SKIP expression, Ki-67 proliferative index over 30%, presence of non-epithelioid type MPM and stage III-IV disease (p < 0.05).
Cox regression analysis revealed that high SKIP expression, high Ki-67 proliferative index and presence of non-epithelioid type MPM are independent factors that affect the survival rate.
Higher SKIP expression is associated with poor prognosis in MPM.
REFERENCES (23)
1.
Gibbs AR. Role of asbestos and other fibres in the development of diffuse malignant mesothelioma. Thorax 1990; 45: 649-654.
2.
O’Reilly KM, McLaughin AM, Beckett WS, et al. Asbestos related lung disease. Am Fam Physician 2007; 75: 683-688.
3.
Montanaro F, Rosato R, Gangemi M, et al. Survival of pleural malignant mesothelioma in Italy: A populationbased study. Int J Cancer 2009; 124: 201-207.
4.
Borasio P, Berruti A, Billé A, et al. Malignant pleural mesothelioma: Clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008; 33: 307-313.
5.
Batirel HF, Metintas M, Caglar HB, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 2008; 3: 499-504.
6.
Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145-152.
7.
Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia Group B. Chest 1998; 113: 723-731.
8.
Kirschner MB, Pulford E, Hoda MA, et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer 2015; 113: 963-969.
9.
Hmeljak J, Erculj N, Dolžan V, et al. Is survivin expression prognostic or predictive in malignant pleural mesothelioma? Virchows Arch 2013; 462: 315-321.
10.
Righi L, Cavallo MC, Gatti G, et al. Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis. Am J Clin Pathol 2014; 141: 816-827.
11.
Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867-873.
12.
Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009; 100: 888-893.
13.
Rossi L, Laas E, Mallon P, et al. Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. Br J Cancer 2015; 113: 996-1002.
14.
Kobayashi M, Huang CL, Sonobe M, et al. Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients. Exp Ther Med 2012; 3: 952-958.
15.
Dahl R, Wani B, Hayman MJ. The Ski oncoprotein interacts with Skip, the human homolog of Drosophila Bx42. Oncogene 1998; 16: 1579-1586.
16.
Prathapam T, Kuhne C, Banks L. Skip interacts with the retinoblastoma tumor suppressor and inhibits its transcriptional repression activity. Nucleic Acids Res 2002; 30: 5261-5268.
17.
Liu X, Ni Q, Xu J, et al. Expression and prognostic role of SKIP in human breast carcinoma. J Mol Histol 2014; 45: 169-180.
18.
Liu G, Huang X, Cui X, et al. High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. Med Oncol 2013; 30: 537.
19.
Wang L, Zhang M, Wu Y, et al. SKIP expression is correlated with clinical prognosis in patients with bladder cancer. Int.
21.
Deraco M, Cabras A, Baratti D, et al. Immunohistochemical evaluation of minichromosome maintenance protein 7 (MCM7), topoisomerase II, and Ki-67 in malignant peritoneal diffuse mesothelioma patients using tissue microarray. Ann Surg Oncol 2015; 22: 4344-4351.
22.
Leong GM, Subramaniam N, Figueroa J, et al. Ski-interacting protein interacts with Smad proteins to augment transforming growth factor-beta-dependent transcription. J Biol Chem 2001; 276: 18243-18248.
23.
Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55: 731-735.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
